Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signali...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Katherine A, Perche, Patrick O, Feldman, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172803/
https://www.ncbi.nlm.nih.gov/pubmed/35685998
http://dx.doi.org/10.2147/CCID.S267217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172803/
https://www.ncbi.nlm.nih.gov/pubmed/35685998
http://dx.doi.org/10.2147/CCID.S267217

Ejemplares similares